Cocrystal Pharma (COCP) Stock Price, News & Analysis

Company Overview

Cocrystal Pharma, Inc. (NASDAQ: COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing a structure-based drug design platform, Cocrystal aims to identify small molecule inhibitors that target essential viral proteins across a broad range of human pathogens. The company’s proprietary platform integrates advanced computational chemistry, protein crystallography, and biophysical screening to accelerate the progression of drug candidates from discovery through clinical evaluation.

Cocrystal’s pipeline includes multiple programs directed against high-priority viral targets such as coronaviruses, influenza viruses, hepatitis C virus and norovirus. The company has advanced lead compounds into preclinical and clinical stages, with certain candidates designed to inhibit viral replication by binding to key enzymes critical for viral lifecycle. In addition to internal discovery efforts, Cocrystal collaborates with academic institutions, contract research organizations and government agencies to leverage external expertise and expand its antiviral portfolio.

Founded in 2010 and headquartered in Bothell, Washington, Cocrystal Pharma operates discovery laboratories in Rochester, New York and maintains partnerships spanning North America and Europe. The company’s global approach addresses both emerging and endemic viral threats, positioning its pipeline to meet unmet medical needs in infectious disease. Regulatory interactions to date have included pre-IND discussions with the U.S. Food and Drug Administration, supporting the advancement of clinical candidates.

Under the leadership of President and Chief Executive Officer Kenneth L. Regan, Cocrystal is guided by an experienced management team with backgrounds in virology, medicinal chemistry and pharmaceutical development. The executive team’s collective expertise in antiviral drug discovery and commercialization strategies underpins the company’s mission to deliver safe and effective therapies for patients affected by serious viral infections worldwide.

Key Stats

• Today's Range: $1.56 to $1.60
• 50-Day Range: $1.41 to $1.70
• 52-Week Range: $1.12 to $3.26
• Volume: 2,389 shs
• Average Volume: 26,316 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

Cocrystal Pharma Stock Analysis - MarketRank™

Cocrystal Pharma scored higher than 51% of companies evaluated by MarketBeat, and ranked 550th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cocrystal Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cocrystal Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cocrystal Pharma are expected to decrease in the coming year, from ($1.85) to ($2.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cocrystal Pharma is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cocrystal Pharma is -1.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cocrystal Pharma has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of Cocrystal Pharma has been sold short.

Short Interest Ratio / Days to Cover

Cocrystal Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cocrystal Pharma has recently decreased by 64.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cocrystal Pharma does not currently pay a dividend.

Dividend Growth

Cocrystal Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.07% of the float of Cocrystal Pharma has been sold short.

Short Interest Ratio / Days to Cover

Cocrystal Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cocrystal Pharma has recently decreased by 64.96%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Cocrystal Pharma this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for COCP on MarketBeat in the last 30 days.

MarketBeat Follows

Only 1 people have added Cocrystal Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.14% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 6.72% of the stock of Cocrystal Pharma is held by institutions.

COCP Stock Analysis - Frequently Asked Questions

How have COCP shares performed this year?

Cocrystal Pharma's stock was trading at $2.02 at the beginning of the year. Since then, COCP stock has decreased by 21.5% and is now trading at $1.5850.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) announced its earnings results on Thursday, May, 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.52) by $0.29.

When did Cocrystal Pharma's stock split?

Shares of Cocrystal Pharma reverse split on Tuesday, October 11th 2022.The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cocrystal Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), OPKO Health (OPK), Advanced Micro Devices (AMD), NIO (NIO), CrowdStrike (CRWD) and Pfizer (PFE).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COCP
• CIK: 1412486
• Web: www.cocrystalpharma.com
• Phone: (305) 425-1780
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cocrystal Pharma: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +284.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -135.12%
• Return on Assets: -102.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.57
• Quick Ratio: 4.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.94 per share
• Price / Book: 1.66

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 2.07